Advertisement
Canada markets closed
  • S&P/TSX

    22,814.81
    +206.78 (+0.91%)
     
  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     
  • DOW

    40,589.34
    +654.27 (+1.64%)
     
  • CAD/USD

    0.7229
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    76.44
    -1.84 (-2.35%)
     
  • Bitcoin CAD

    94,132.77
    +1,253.68 (+1.35%)
     
  • CMC Crypto 200

    1,378.40
    +47.79 (+3.59%)
     
  • GOLD FUTURES

    2,385.70
    +32.20 (+1.37%)
     
  • RUSSELL 2000

    2,260.07
    +37.09 (+1.67%)
     
  • 10-Yr Bond

    4.2000
    -0.0560 (-1.32%)
     
  • NASDAQ

    17,357.88
    +176.16 (+1.03%)
     
  • VOLATILITY

    16.39
    -2.07 (-11.21%)
     
  • FTSE

    8,285.71
    +99.36 (+1.21%)
     
  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     
  • CAD/EUR

    0.6654
    -0.0013 (-0.19%)
     

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?